ASCO: Dual Immune Tx Tag Teams Melanoma

CHICAGO (MedPage Today) -- The combination of ipilimumab and nivolumab may boost response rates against metastatic melanoma without excessive toxicity, a phase I trial showed. via MedPageToday.com - medical news plus CME for physicians Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2013/06/asco-dual-immune-tx-tag-teams-melanoma.html